New Combivent

UDVs™

A convenient solution for greater Oompah in COPD

Is *Easi-Breathe* possible? ..it is now!

NOW By popular demand... Salamol *Easi-Breathe* too!

50-75% of patients are unable to use metered-dose inhalers (MDIs) properly[1,2,3,4], but they are still the most widely used asthma device[3].

and in more ways than one...

'Preventer'

- Beclazone *Easi-Breathe* is reassuringly familiar in shape for your patients.
- Remarkably easy handling. All your patient has to do is *Open, Breathe, Close.*



- Beclazone *Easi-Breathe* is supplied with a small volume spacer (Optimiser) for your high dose inhaled steroid patients.
- Beclazone *Easi-Breathe* is identical in price to our standard Beclazone MDIs[5].
- Beclazone *Easi-Breathe* is 20-22% less in cost than the originator BDP MDIs and offers significant savings compared to other breath-operated dry powder devices[6,7].

'Reliever'

- The addition of Salamol *Easi-Breathe*, means that you can now prescribe the same, simple and easy to use *Easi-Breathe* inhaler for the relief of asthma symptoms.
- As you would expect from Baker Norton, Salamol *Easi-Breathe* is the most cost effective Salbutamol breath-operated inhaler* and offers substantial savings compared to other breath-operated aerosol and dry powder inhalers[6,7].

*per equivalent dose

℞ **Beclazone *Easi-Breathe***

Beclomethasone Dipropionate BP 50, 100 & 250 microgram inhalers

℞ **Salamol *Easi-Breathe***

Salbutamol BP 100 microgram inhaler

BAKER NORTON

Quality medicines at sensible prices

Designed to save lives *Priced* to save millions

PRESCRIBING INFORMATION

Presentations: Pulmicort Respules, (2ml single dose unit ampoules) containing 0.25mg/ml or 0.5mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules: Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older): 0.5-1mg twice daily. Children (3 months to 12 years): 0.25-0.5mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contra-indications, warnings, etc.:** Contra-indications: Hypersensitivity to any of the constituents. Special warnings and precautions: Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care; see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side-effects:** Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a β_2-agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening. **Legal status:** POM. **Basic NHS price:** Pulmicort Respules 0.25mg/ml (20 single dose units) £32.00. Pulmicort Respules 0.5mg/ml (20 single dose units) £44.64. **Product licence nos.:** Pulmicort Respules 0.25mg/ml PL 0017/0309. Pulmicort Respules 0.5mg/ml PL 0017/0310. **Name and address of product licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.

Inspired control you can trust

Astra Pharmaceuticals Ltd.,
Home Park,
Kings Langley,
Herts WD4 8DH.

ASTRA
Astra Pharmaceuticals

® Registered Trademark
Date of preparation: May 1995
P.Res. 0382

Pulmicort®
Respules®
BUDESONIDE
Nebulised Steroid Control

...opionate)
...scribing Information
... to the full data sheet before
...)
...ically active corticosteroid for
...ctic management of asthma.
...and administration
...halation only. Use regularly. Onset
...rapeutic effect usually occurs in
... days. *Adults:* 100 to 1,000
...grams twice daily. *Children aged 4*
...ver: 50 to 100 micrograms twice
... Equivalent disease control usually
... half the daily dose of other
...inhaled steroids.
...ersensitivity.
...recautions [illegible]
...uiescent pulmonary [illegible]
...*r unstable asthma:* [illegible]
...nedical advice if [illegible]
...ronchodilator use [illegible]
...ess effective. Consider [illegible]
...teroids and/or [illegible]
...nhaled corticosteroids. [illegible]
...xacerbations in the [illegible]
...ymptoms: Not for relief of [illegible]
...ymptoms. A short-acting [illegible]
...ronchodilator is required. *Systemic*
...ffects: Adrenal function and reserve
...sually remain within the normal range.
...ome systemic effects may occur [illegible]
...mall proportion of adults after lo...
...erm treatment at high doses. Som...
...iochemical changes reported [illegible]
...hildren, but no stunting of growth
...bserved. *Transfer from oral steroids:*
...pecial care is needed. Monitor adrenal
...unction. Do not stop Flixotide abruptly.
...onsider additional corticosteroid
...herapy in situations likely to produce
...tress. *Pregnancy and lactation:* Experience
... limited. Balance risks against benefits.
...ide effects Candidiasis of mouth and
...hroat. Hoarseness. Rarely, cutaneous
...ypersensitivity. *Paradoxical bronchospasm:*
...ure alternative therapy.
...resentation and Basic NHS cost
...lixotide Accuhaler: 60 inhalations.
...0 micrograms – £8·2... [illegible] micrograms
... £12·80. 250 micrograms – [illegible]
...00 micrograms – £40·23. *Flixotide*
...haler: 120 actuations. 25 micrograms –
...6·86. 50 micrograms – £11·43.
...25 micrograms – £22·86.
...50 micrograms – £38·86.
...lixotide Diskhaler: 14 four-place disks
...ith Flixotide Diskhaler. 50 micrograms
... £8·23. 100 micrograms – £12·80.
...50 micrograms – £24·23.
[illegible]
...4 four-place disks. 50 micrograms – £7·66
...00 micrograms – £12·23.
...50 micrograms – £23·66.
...00 micrograms – £39·66.
...iskhaler and Inhaler Hospital pac...
...so available.
...roduct licence numbers [illegible]
...949/0227, 10949/0228, 10949/[illegible]
...949/0001, 10949/0002, 10949/0003,
...949/0004, 10949/0005, 10949/0006,
...949/0007, 10949/0008.
...roduct licence holder Glaxo
...armaceuticals UK Limited, Stockley
...rk West, Uxbridge UB11 1BT.
POM



ALLEN & HANBURYS
Further information is available
on request from:
Allen & Hanburys Limited
Uxbridge, Middlesex UB11 1BT
...cuhaler, Diskhaler and Flixotide are trade
marks of the Glaxo Group of Companies

June 1995

FLIXOTIDE▼
...ticasone propionate



Designed for control, with safety in mind.

BREVIATED PRESCRIBING INFORMATION

sentation UNIPHYLLIN CONTINUS tablets contain eophylline BP in a controlled release system. UNI-YLLIN CONTINUS tablets 400 mg are white, capsule-aped, scored tablets with the logo NAPP U400 bossed on one side and UNIPHYLLIN on the other. IPHYLLIN CONTINUS tablets 300 mg are white, cap-e-shaped, scored tablets with U300 embossed on e side. UNIPHYLLIN CONTINUS tablets 200 mg are ite, capsule-shaped, scored tablets with U200 bossed on one side. Uses Theophylline is a bron-dilator. In addition it affects the function of a num- of cells involved in the inflammatory processes ociated with asthma and chronic obstructive airways ease. Of most importance may be enhanced sup-essor T-lymphocyte activity and reduction of inophil and neutrophil function. These actions may tribute to anti-inflammatory prophylactic activity in hma and chronic obstructive airways disease. For the atment and prophylaxis of bronchospasm associated h asthma, emphysema and chronic bronchitis. Also licated in adults for the treatment of cardiac asthma d left ventricular or congestive cardiac failure. sage and administration *NB* Tablets should be allowed whole and not chewed. *Adults:* The usual intenance dose for elderly patients or those less n 70 kg body weight is 300 mg, 12-hourly follow- an initial week of therapy on 200 mg, 12-hourly. e usual maintenance dose for patients of 70 kg body ight or over is 400 mg, 12-hourly following an initial ek of therapy on 200 mg or 300 mg, 12-hourly. *ildren:* Not recommended for children under seven rs of age. The maintenance dose is 9 mg/kg twice ly. Some children with chronic asthma require and erate much higher doses (10-16 mg/kg twice daily). wer dosages (based on usual adult dose) may be uired by adolescents. It may be appropriate to minister a larger evening or morning dose in some tients, in order to achieve optimum therapeutic ect when symptoms are quite severe, e.g. at the time the 'morning dip' in lung function. In patients whose ht time or day time symptoms persist despite other rapy and who are not currently receiving theo-ylline, then the total daily requirement of UNI-YLLIN CONTINUS tablets (as specified above) may be ded to their treatment regimen as either a single ening or morning dose. *Elderly:* The initial dose ould be 200 mg, 12-hourly increasing to 300 mg, 12-urly. Contra-indications Should not be given con-mitantly with ephedrine in children. Precautions d warnings The following increase clearance and it y therefore be necessary to increase dosage to sure a therapeutic effect: phenytoin, carbamazepine, mpicin, sulphinpyrazone and barbiturates. Smoking d alcohol consumption can also increase clearance of eophylline. The following reduce clearance and a duced dosage may therefore be necessary to avoid e-effects: allopurinol, cimetidine, ciprofloxacin, ery-omycin, thiabendazole, isoprenaline, fluvoxamine, oxazine hydrochloride and oral contraceptives. ctors such as viral infections, liver disease and heart lure also reduce theophylline clearance. The pokalaemia resulting fom beta$_2$ agonist therapy, roids, diuretics and hypoxia may be potentiated by nthines. Particular care is advised in patients suffering m severe asthma who require hospitalisation. It is ommended that serum potassium levels are moni-red in such circumstances. Safety in human pregnancy has not been established. Side-effects The side e-effects usually associated with theophylline and nthine derivatives such as nausea, gastric irritation, adache and CNS stimulation is significantly reduced en UNIPHYLLIN CONTINUS tablet preparations are ven. Furthermore, the side effects can be minimised dose titration downwards. *Transferability:* it is not ssible to ensure bioequivalence between different stained release theophylline products. Therefore it ould be emphasised that patients, once titrated to an ective dose, should not be changed from UNI-YLLIN CONTINUS tablet preparations to other slow sustained release xanthine preparations without re-ration and clinical assessment. Legal category P. ckage quantities and basic NHS price UNIPHYLLIN ONTINUS tablets 400 mg - 56's: £7.32; 250's. 2.36; 1,000's: £125.29. UNIPHYLLIN CONTINUS blets 300 mg - 56's: £6.17; 250's. £27.89. UN-YLLIN CONTINUS tablets 200 mg - 56's: £4.05. oduct licence numbers UNIPHYLLIN CONTINUS blets 400 mg - PL 0337/0074. UNIPHYLLIN CONTI-S tablets 300 mg - PL 0337/0129 UNIPHYLLIN CON-US tablets 200 mg - PL 0337/0057. Product licence lder Napp Laboratories Limited, Cambridge Science k, Milton Road, Cambridge CB4 4GW, UK. Tel 223 424444. Member of Napp Pharmaceutical oup. Further information is available from Napp boratories Limited. ® The NAPP device, UNIPHYLLIN d CONTINUS are Registered Trade Marks © NAPP boratories Limited 1995

ference: 1. Kidney J, Dominguez M
/ or PM, et al. In press..

te of preparation: May 1995.

NAPP

For over 50 years, theophylline has been regarded as a bronchodilator. New evidence demonstrates that this is only part of the story.

UNIPHYLLIN CONTINUS tablets are now believed to exert an anti-inflammatory action. They therefore present a convenient and acceptable choice for preventive therapy - and add a new dimension to asthma management.

DUAL ACTION

Uniphyllin®

CONTINUS® TABLETS THEOPHYLLINE BP

Breathing new life into asthma therapy



Prescribing Information ▼®FORADIL eformoterol fumarate ***Presentation*** 12 micrograms dry powder inhalation capsules for use with breath activated inhaler device. ***Indications*** Regular maintenance treatment of bronchospasm in patients with reversible obstructive airways disease. ***Dosage*** Adults including the elderly: 1-2 capsules twice daily. Not recommended for children. ***Contra-indications*** Hypersensitivity to eformoterol fumarate or lactose. ***Precautions*** Steroid treatment should continue unchanged. FORADIL is not for relief of acute symptoms – a short- acting $ß_2$-agonist is required. Thyrotoxicosis, severe cardiovascular disorders, dysrhythmia, hypokalaemia, diabetes mellitus. Pregnancy and lactation. Avoid use with ß-adrenergic blockers. ***Side-effects*** *Occasionally*: tremor, palpitations, headache. *Rarely*: muscle cramps, myalgia, tachycardia, agitation, dizziness, insomnia, paradoxical bronchospasm, oropharyngeal irritation. ***Legal category*** POM. ***Packs*** Dry powder capsules of 12 micrograms (PL0001/0192) together with an inhaler device, in calendar packs of 56 (basic NHS price £24.00). ® denotes registered trademark.

Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex, RH12 4AB. Telephone (01403) 272827.
Date of preparation February 1995.

Geigy
Asthma Care

Taking charge of clinical risk..

CLINICAL RISK MANAGEMENT

BMJ Publishing Group

Edited by CHARLES VINCENT

Risk management has become a major issue in health care, aimed at reducing the probability of patients being harmed during treatment and minimising the subsequent consequences. This timely book is a unique source of reference for managers and clinicians keen to develop effective risk management, containing:

- Practical advice on implementation, the underlying principles, and recognising potential risks
- Chapters on the clinical applications in various specialties, including anaesthesia, obstetrics, paediatrics, and psychiatry
- Contributions from leaders in the field from the UK and USA
- All the information needed to investigate complaints, deal with claims in the optimum way, and reduce the impact of litigation

The definitive guide to improving the quality of care for your patients

Order your copy now

ISBN 0 7279 0947 9 588 pages January 1996
UK £34.95; Overseas £38.00 (BMA members £32.95; £36.00)

BMJ Publishing Group

...and other management concerns

Quality and Safety in Anaesthesia

Edited by Jonathan Secker Walker

"It is satisfying to find a text that states what quality in anaesthetic practice is really about."
Today's Anaesthetist



ISBN 0 7279 0828 6
192 pages
UK £16.95;
Overseas £19.00
(BMA members £15.95; £18.00)

Outcomes into Clinical Practice

Edited by Tony Delamothe

A ground-breaking book on outcomes research, focusing on the opportunities to improve clinical effectiveness and set standards for good practice.



ISBN 0 7279 0888 X
169 pages UK £17.95; Overseas £20.00
(BMA members £16.95; £19.00)

Rationing in Action

Expert advice on the implications of rationing to health providers and their patients.



ISBN 0 7279 0813 8 160 pages
UK £10.95;
Overseas £13.00
(BMA members £9.95; £12.00)

Management for Doctors

Edited by Jenny Simpson and Richard Smith

"An insightful and inspiring guide for any doctor who wants to know and understand more about NHS management."
Journal of the Royal College of Physicians



ISBN 0 7279 0858 8
200 pages UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)

ORDER FORM

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House**

Please send me

- ☐ copy/ies of **Clinical Risk Management**
- ☐ copy/ies of **Quality and Safety in Anaesthesia**
- ☐ copy/ies of **Outcomes into Clinical Practice**
- ☐ copy/ies of **Rationing in Action**
- ☐ copy/ies of **Management for Doctors**

BMA Membership No. _____

Name _____
(Print clearly)

Address _____

_____

_____ **Postcode** _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my American Express/Visa/Mastercard

Card No. _____ **Exp** _____

Signature _____

☐ Please send me a **BMJ Publishing Group Catalogue**

Presentation: Bricanyl Turbohaler. Dry powder inhaler delivering 0.5 mg terbutaline sulphate per actuation. **Uses:** Relief and prevention of bronchospasm in bronchial asthma and bronchopulmonary disorders in which bronchospasm or reversible airways obstruction is a complicating factor. **Dosage and administration: Adults and children** (including elderly): One inhalation (0.5 mg) as required. Not more than 4 inhalations/day. **Contra-indications, warnings, etc:** Contra-indications: Sensitivity to terbutaline sulphate. Precautions: Care should be taken in patients with myocardial insufficiency or thyrotoxicosis. Additional blood glucose measurements are initially recommended in diabetic patients. If treatment becomes less effective or shorter acting, the patient's general condition should be reviewed. Do not use in patients with hypertrophic cardiomyopathy. Potentially serious hypokalaemia may result from β_2-agonist therapy. Administer with caution during the first trimester of pregnancy. Do not administer concurrently with non-selective ß-blockers. Use with caution with other sympathomimetics. **Side effects:** Tremor, tonic cramp and palpitations are all characteristic of sympathomimetic amines. A few patients feel tense. **Basic NHS price:** Bricanyl Turbohaler (100 doses) £7.96. **Legal category:** POM. **Product licence no.:** PL 0017/0241.

Presentation: Pulmicort Turbohaler 100: 100µg/puff budesonide dry powder inhaler containing 200 actuations. Pulmicort Turbohaler 200: 200µg/puff budesonide dry powder inhaler containing 100 actuations. Pulmicort Turbohaler 400: 400µg/puff budesonide dry powder inhaler containing 50 actuations. **Uses:** Bronchial asthma. **Dosage and administration:** Individualise dose. Adults (including elderly): 200-1600µg daily in divided doses. Children: 200-800µg daily in divided doses. Maintenance: Use lowest possible dose. Brush the teeth and rinse the mouth out with water after each use. **Contra-indications, warnings, etc.:** Contra-indications: Active pulmonary tuberculosis. Precautions: Special care is needed in patients with quiescent lung tuberculosis, fungal and viral infections in the airways. Avoid administration during pregnancy. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to treatment with Pulmicort demands special care. See data sheet for further details. Side-effects: Mild irritation in the throat, hoarseness and oral candidiasis occur in some patients. **Basic NHS price:** Pulmicort Turbohaler 100 (200 actuations) £18.50. Pulmicort Turbohaler 200 (100 actuations) £18.50. Pulmicort Turbohaler 400 (50 actuations) £18.50. **Legal status:** POM. **Product licence nos.:** Pulmicort Turbohaler 100 PL 0017/0319. Pulmicort Turbohaler 200 PL 0017/0272. Pulmicort Turbohaler 400 PL 0017/0271.

For further information contact the Product Licence holder:
Astra Pharmaceuticals Limited, Home Park, Kings Langley,
Herts WD4 8DH.

®Pulmicort, Bricanyl and Turbohaler are registered trademarks of Astra Pharmaceuticals Limited.

Date of preparation: August 1995.

ASTRA

Astra Pharmaceuticals

TURB 950525B

Bricanyl®
Turbohaler®
TERBUTALINE SULPHATE

Pulmicort®
Turbohaler®
BUDESONIDE

DESIGNED FOR EFFICIENCY